Welcome to our dedicated page for Amarin Plc news (Ticker: $AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amarin Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amarin Plc's position in the market.
Rhea-AI Summary
Amarin Corporation plc (AMRN) will host a conference call to discuss its fourth quarter and year-end 2023 results on February 29th, 2024. The call will include a Q&A session and highlights from 2023. Shareholders can submit questions through Say Technologies for the earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced a letter to shareholders highlighting significant actions taken to strengthen the company, including leadership restructuring, operational improvements, and financial discipline. The company's focus on extending market leadership in the U.S., accelerating revenues in Europe, and advancing market access in the Rest of World (RoW) positions it for shareholder value in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (AMRN) reported unaudited total revenues of $72-74 million in Q4 2023, ending the year with a cash position of $321 million and delivering full-year positive cash flow of ~$10 million. The company's 2024 priorities include accelerating revenue in key European launch markets, retaining IPE market leadership in the US, and maximizing patient uptake in Rest of World (RoW) through partnerships. Amarin also announced a plan to initiate a share repurchase program of up to $50 million. The company will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.87%
Tags
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) is set to participate in the 42nd Annual JP Morgan Healthcare Conference, with President and CEO Patrick Holt scheduled to present on January 10, 2024. The webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
News
Rhea-AI Summary
Sarissa Capital Management LP (Sarissa) issued a statement regarding Amarin Corporation plc (NASDAQ: AMRN), expressing belief in the significant undervaluation of Amarin's stock. Sarissa remains a long-term shareholder and has been purchasing shares at depressed prices, never having sold any shares. The company has made progress in reorganizing its leadership team, streamlining its U.S. business, reworking Europe's commercial infrastructure, achieving national reimbursement approvals and launches of Vazkepa in Europe and securing international partnership deals. Sarissa acknowledges that turning around companies takes time and is pleased with Amarin's progress, expecting the value to be reflected in the stock price over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced findings from new REDUCE-IT analyses, revealing that VASCEPA/VAZKEPA significantly reduced the risk of first and total cardiovascular events in a subgroup of statin-treated patients with Metabolic Syndrome but without diabetes. The results were presented at the American Heart Association Scientific Sessions 2023 and simultaneously published in the European Heart Journal Open. The findings support IPE as an important therapeutic option for patients with Metabolic Syndrome at high cardiovascular risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Amarin Corporation reported total net revenues of $66 million in the third quarter of 2023. They achieved positive cash flow of $8 million, marking the fifth consecutive quarter of cash positive operations. The company's quarter-ending cash position was $321 million. Amarin continues to deliver significant U.S. profit through the extended lifecycle and market leadership of their branded product VASCEPA®. They have also made progress with the early launch of VASCEPA® in European countries driven by new leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amarin Corporation plc has appointed Jonathan Provoost as its new Executive Vice President, Chief Legal & Compliance Officer. Provoost brings over 20 years of corporate legal experience, having served in various leadership roles in pharmaceutical companies. He will join Amarin on November 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary
Amarin announces new research from the REDUCE-IT trial on the effects of VASCEPA/VAZKEPA in high-risk patient subgroups. The research includes reduction in CV events in patients with Metabolic Syndrome but without diabetes, mechanistic analyses of EPA and DHA, and demographic/clinical characteristics of US patients with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
News
Rhea-AI Summary
Amarin Corporation to host conference call to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
Amarin Corp Plc
Nasdaq:AMRN
AMRN Rankings
AMRN Stock Data
365.23M
383.11M
1.54%
23.81%
4.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
DUBLIN 2
About AMRN
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.